CCI Approves Deal Involving Three GlaxoSmithKline Group Entities

The Competition Commission of India (CCI) on Monday approved the acquisition by GlaxoSmithKline Consumer Healthcare Overseas and GlaxoSmithKline Consumer Healthcare UK Trading (Acquirers) of shareholding in GlaxoSmithKline Asia Private (Target) under Section 31(1) of the Competition Act, 2002.

The proposed combination involves the collective acquisition of 100 per cent shares of the target by the acquirers. Further, prior to the proposed combination, GSKAPL will acquire the trademarks pertaining to “Iodex” and “Ostocalcium” brands in India along with the legal, economic, commercial and marketing rights of such brands and other associated assets (GSK Consumer Brands) from GlaxoSmithKline Pharmaceuticals.